Research on the Role of SLC1A5 in the Development of Esophageal Cancer

Study Overview
=================
Brief Summary
-----------------
To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.

Detailed Description
-----------------
This will be an observational study. The investigators will aim to enroll 100 male and female adult patients (aged 18 years and over) of all ethnicities/races, who have been referred to the Fourth Affiliated Hospital of Guangxi Medical University for esophageal cancer. The investigators will be using a standardized data collection form. This is an observational study in which standard of care will be practiced and the patients are not placed at additional risk from participating in this study. However, as the investigators are collecting data prospectively, all participants will sign consent. An attempt will be made to see if there is a correlation between the expression of SLC1A5 with esophageal cancer.

Official Title
-----------------
Research on the Role of the Amino Acid Transporter SLC1A5 in the Development of Esophageal Cancer

Conditions
-----------------
Amino Acid Transport Disorder, Esophageal Cancer

Intervention / Treatment
-----------------
* Other: SLC1A5 expression


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with histologically proven esophageal cancer; Age ≥18 years; All patients must sign consent forms voluntarily; Exclusion Criteria: Inability to obtain histologic proof of malignancy. Age <18 years;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cancer tissues<br>SLC1A5 expression of esophageal cancer tissues from patients | Other: SLC1A5 expression<br>* To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.<br>|
| paired adjacent tissues<br>SLC1A5 expression of paired adjacent esophageal tissues from patients | Other: SLC1A5 expression<br>* To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| optical density (ODs) of each slice by immunohistochemistry assay | For immunohistochemistry assay： Briefly, the samples will be cut into slices, which will be stained with standard steps. Finally, three high power fields will be randomly selected from each slice and the average optical density (OD) will be measured in each field. | within one year (plus or minus 1 month) after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SLC1A5 expression detected by WesternBlot | Western blot assay will be done by comparing the intensity of bands. To start with, xray film will be scanned on a flat-bed scanner. Then the grayscale image will be analyzed with software. Finally the Gray Value of each band will be obtained for analysis. | within one year (plus or minus 1 month) after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
esophageal cancer, SLC1A5